aceclofenac has been researched along with methotrexate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Garg, NK; Jain, A; Jain, S; Katare, OP; Sharma, G; Singh, B; Tyagi, RK | 1 |
| Biju, IK; Manappallil, RG; Peringat, J; Prasan, D | 1 |
| Kumar, R; Negi, S; Sharma, P; Tandel, N; Tyagi, RK | 1 |
2 review(s) available for aceclofenac and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Therapy, Combination; Inflammation; Methotrexate; Mice | 2023 |
4 other study(ies) available for aceclofenac and methotrexate
| Article | Year |
|---|---|
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Functionalized Lipid-Polymer Hybrid Nanoparticles Mediated Codelivery of Methotrexate and Aceclofenac: A Synergistic Effect in Breast Cancer with Improved Pharmacokinetics Attributes.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Diclofenac; Female; Humans; Interleukin-1beta; Interleukin-6; Lipids; Matrix Metalloproteinase 1; MCF-7 Cells; Methotrexate; Mice; Mice, Inbred BALB C; Nanoparticles; Polymers; Tumor Necrosis Factor-alpha | 2017 |
Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Marrow Cells; Bone Marrow Diseases; Diclofenac; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Methotrexate; Oral Ulcer | 2018 |